SEATTLE, April 10, 2020 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global bipolar disorder treatment market is estimated to be valued at US$ 7,288.3 million in 2019 and is expected to exhibit a CAGR of 5.2% over the forecast period (2019-2027).
Key Trends and Analysis of the Global Bipolar Disorder Treatment Market:
Key trends in the market include increasing prevalence of mental disorders, increasing number of product launches, and increasing collaboration and acquisition activities by key market players.
Furthermore, according to the Organisation for Economic Co-operation and Development (OECD)/ European Union 2018 Report, around 84 million of European population has some mental health problems.
Request for Sample PDF copy @ https://www.coherentmarketinsights.com/insight/request-sample/2605
The increasing product launches is expected to drive growth of the global bipolar disorder treatment market over the forecast period. For instance, in July 2017, Otsuka Pharmaceutical Co., Ltd. and H.Lundbeck A/S received the U.S. FDA approval for ABILIFY MAINTENA (aripiprazole), an extended-release injectable suspension, for the maintenance monotherapy treatment of bipolar I disorder (BP-I) in adults.
Furthermore, key players operating in the market are focused on increasing their manufacturing capabilities by launching new production lines, in order to expand their product offerings in the market. For instance, in May 2018, AstraZeneca entered into a license agreement with Luye Pharma Group, Ltd. for the sales and license of rights to Seroquel and Seroquel XR in the U.K., China, and other international markets, which include Brazil, Australia, Saudi Arabia, Mexico, South Korea, Thailand, Argentina, Malaysia, and South Africa.
Read Report Summary @ https://www.coherentmarketinsights.com/market-insight/bipolar-disorders-treatment-market-2605
Key Market Takeaways:
Key players operating in the global bipolar disorder treatment market include—
Takeda Pharmaceutical Company Limited, Pfizer, Inc., Allergan plc, Otsuka Holdings Co. Ltd., Johnson & Johnson, Eli Lilly and Company, GlaxoSmithKline plc, AstraZeneca Plc, Novartis International AG, AbbVie Inc., H. Lundbeck A/S, Minerva Neurosciences, Sumitomo Dainippon Pharma Co., Ltd., Intra-Cellular Therapies Inc., Gedeon Richter Plc., and Indivior PLC.
Buy this Report Now @ https://www.coherentmarketinsights.com/insight/buy-now/2605
Market Segmentation:
Did not find what you were looking for? Here are some similar topics:
NORTH AMERICA SYNTHETIC OPIOIDS MARKET
Synthetic Opioids (CVIS) are opioid receptor agonists and act primarily on the brain and spinal cord and are used for pain relief. Most commonly prescribed synthetic opioids include, methadone, fentanyl and meperidine. Increasing prevalence of cancer is expected to boost growth of North America synthetic opioids market over the forecast period.
Read more @ https://www.coherentmarketinsights.com/market-insight/north-america-synthetic-opioids-market-3660
NEUROPATHIC PAIN MARKET
Neuropathic pain is a condition which involves pain caused due to damage or diseases affecting the nervous system. These conditions may include diseases such as diabetes causing diabetic neuropathy, chemotherapy induced neuropathic pain, and trigeminal neuralgia. Diabetic neuropathy is the damage caused to the nerve due to diabetes which often leads to pain and numbness in feet or lower legs.
Read more @ https://www.coherentmarketinsights.com/market-insight/neuropathic-pain-market-3656
CONTACT: Mr. Shah Coherent Market Insights 1001 4th Ave. #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: sales@coherentmarketinsights.com